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Introduction
The lifetime prevalence of bipolar disorder Type 1 (BD) is
approximately 1% in the US and Europe, and likely equally high
in Southern Africa.1,2 BD is associated with a high level of
mortality (between 10-20% of individuals affected with BD
successfully commit suicide) and morbidity (BD is estimated as
one of the top ten causes of disability worldwide).3-5 An earlier
age of disease onset, increased number of episodes and
hospitalisations for mania and depression, and the presence of
psychotic symptoms are markers of a more severe disease
phenotype.6-8 Previous research has not examined associations
between phenotype severity and glutamate signalling in BD,
although variants within brain derived neurotrophic factor
(BDNF) may be associated with indices of severity in BD.9-11
Glutamate signalling is involved in brain development and
synaptic plasticity, both of which are modified in individuals
affected with BD, and have been implicated in its aetiology.12,13
A range of psychotropics involved in the treatment of BD alter
glutamatergic function; for example, lamotrigine inhibits the
release of glutamate and lithium affects glutamate receptor
function.14 It has also been observed that variation in the
glutamate receptor encoding gene, GRIK4 (rs1954787) makes
subjects with depressive episodes more likely to respond to
citalopram.15 Fallin et al. found that the glutamatergic genes
most likely to be associated with BD rather than schizophrenia
(SZ) were GRM3 and GRIN2B, and replicated previous findings
of strong associations between DAOA and BD diagnosis.16
Glutamate receptor, metabotropic 3 (GRM3) encodes
subunit 3 of the Group II metabotropic glutamate receptors
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a 4-fold increased risk of lifetime history of psychotic symptoms, and the specific variants within the gene pair, DAOA and GRIN2B,
had a significant interaction with the number of hospitalisations for mania, with lowest admission rates associated with both pairs
of ancestral alleles. Conclusion: In BD, variations in glutamatergic genes may influence phenotypes related to the severity of
illness. Speculatively, newly derived genes associated with various evolutionary advantages, may also increase the risk for more
severe BD. These preliminary findings deserve validation in a larger cohort.
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(mGluR). In glutamate receptor, metabotropic 2 (GRM2) and
GRM3 knockout mice, Lyon et al. showed a compensatory up-
regulation of remaining group II mGluRs and the N-methyl
D-aspartate (NMDA) receptor subunit 2A (NR2A) expression,
and down-regulation of glutamate transporter expression.17
Post-mortem studies have suggest altered GRM3 expression in
BD.18 Crespi et al. identified GRM3 as one of 14 genes with
significant evidence of selection in human populations.19 GRM3
modulates glutamate neurotransmission by regulating the
excitatory amino acid transporter 2 (EEAT2). Egan et al. have
demonstrated that decreased levels of EEAT2 are associated
with a GRM3 SNP (rs6465084), which has a weak association
with SZ.20 Egan et al. have also demonstrated that individuals
who are homozygous A for GRM3 rs6465084 have lower levels
of N-acetylaspartate, an indirect indicator of synaptic function
and glutamate levels and suggests that GRM3 rs6465084 has an
effect on GRM3 transcript expression.20
Ionotropic glutamate receptor, N-methyl D-aspartate 2B
(GRIN2B) encodes the NR2B subunit of the NMDA receptor.
Mice with enhanced NR2B function show supernormal learning
and memory function, while BD sufferers consistently show
impairment in working memory.21 Associations have been
observed between several polymorphisms in the GRIN2B gene
and the 12p13.1-p12.3 region (containing the GRIN2B gene)
and BD.16,22,23 Miyatake et al. have observed that the T allele of
the GRIN2B rs1019385 SNP results in increased luciferase
transporter activity in the presence of nerve growth factor
(NGF).24 The presence of a G allele had no effect on reporter
activity, suggesting that GRIN2B rs1019385 may have a role in
transcriptional control of the GRIN2B transcript.24
The G72 gene product, D-amino-acid oxidase activator
(DAOA), activates the peroxisomal protein D-amino-acid
oxidase (DAO).25 This protein (G30) degrades D-serine, which
acts, similar to glycine, as a coactivator on the “glycine binding
site” of the glutamatergic NMDA receptor. Hashimoto et al.
showed that the percentage of D-serine in the total serine in the
cerebrospinal fluid of drug naïve SZ patients was significantly
lower than that of control samples.26 Genetic variants of
G72/G30 have been found to be associated with BD and
SZ.16,27-32 In some populations, the at-risk haplotypes are shared
between SZ and BD.31 The pathogenic mutations have not yet
been identified but might be located in the vicinity of the
G72/G30 gene complex or in the regulatory region.30
Method
Subjects
The cohort comprised of two groups: a group of BD Type 1
affected individuals (cases) and the background population
group (controls). Blood samples were previously obtained, with
the appropriate written informed consent. This study was
approved by the University of Cape Town Health Science
Faculty Research Ethics Committee (081/96) and is in
accordance with the guidelines of the Helsinki Declaration of
2000.
The Division of Human Genetics has a BD database
consisting of 883 individuals comprising 185 families. For the
purposes of this study, the cases consisted of 191 individuals
specifically diagnosed with BD Type 1 with the Structured
Clinical Interview for the DSM-IV (SCID). This group
comprised of 87 (46%) males and 104 (54%) females of ages
ranging from 22 to 91 years. Subjects included 103 (54%)
individuals of mixed ancestry and 88 (46%) Caucasian
individuals. The cases included 95 individuals from 36 families
that were related to at least one other case. The age of onset,
number of depressive episodes, number of hospitalisations
due to mania and depression of each of the cases were noted,
as well as history of psychotic symptoms. The control group
consisted of 188 unrelated individuals not diagnosed with any
psychiatric disorder, and similar to the cases in terms of age,
gender and ethnicity.
DNA Analysis
The following SNPs were chosen for genotyping based on
previous association to either BD or SZ: GRM3 rs6465084
(intronic), GRIN2B rs1019385 (5’ upstream), and DAOA
rs701567 (intronic).1-4 Gene sequences were obtained from the
National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov) and Ensembl
(http://www.ensembl.org/index.html) databases and the SNP
locations were determined. DNA concentration and integrity
was determined by spectrophotometric quantification and
agarose gel electrophoresis, respectively. Polymerase chain
reaction (PCR) was performed on genomic DNA, according to
standard procedures, for each of the SNPs in the candidate
genes. The polymorphisms were genotyped using the
SNaPshot™ multiplex ready reaction mix (Applied Biosystems,
Warrington, UK) and the ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, CA, USA). Genotyping results were
validated by cycle sequencing using BigDye Terminator Mix
(Applied Biosystems, CA, USA) and the ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, CA, USA). 
Statistical Analysis
For the case-control analysis, one individual from each family
was randomly selected, leaving 132 unrelated cases. For this
analysis, logistic regression was used. 
The case-only analyses involved all 191 cases, which were
adjusted for relatedness. We used generalised linear models
for all the association tests. For age of onset, we used a normal
family with an identity link; for each of the three outcomes: (i)
number of depressive episodes, (ii) hospitalisations due to
mania and (iii) hospitalisations due to depression, we used the
Poisson family with a log link and for dichotomous history of
psychosis, a binomial family with logit link. There were only 4
GRM3 rs6465084 homozygous G cases. We therefore grouped
them with the heterozygotes for the case-only analyses.
Genotypes were coded as categories for the single-SNP
analyses, and numerical (number of minor alleles) for testing
interactions. 
All of the six outcomes analysed (case-control, age of onset,
number of depressive episodes, hospitalisations due to mania,
hospitalisations due to depression, and history of psychotic
events), were tested for an interaction between the three SNPs.
When this was not significant, we tested all pairwise
interactions between SNPs and where those were not
significant, we tested the individual SNPs (main effects). All
analyses were adjusted for gender, ethnicity and duration of
disease as fixed effects and family-membership as random
effect.
Statistical analyses were done with R, a language and
environment for statistical computing and graphics, and R
packages nlme and MASS (http:\\www.R-project.org).
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Results
Case-control analysis (132 cases; 188 controls)
The differences in the genotype and allele frequencies
between cases and controls were not significant. Neither were
any SNP-interactions on case-control status significant (results
not shown). The allele frequencies for each of the SNPs
obtained from the cases and controls in the current study, are
displayed in Table I.
Case-only analysis (n=191)
All the results presented here were adjusted for gender, ethnic
group, duration of disease and family-membership.
We did not find any significant association between the
SNPs GRM3 rs6465084, GRIN2B rs1019385, DAOA rs701567
and main effects or interactions on age of onset (n=124),
number of depressive episodes (n=130), or number of
hospitalisations for depression (n=171). However, a significant
association between GRM3 rs6465084 and history of
psychosis (63% with a history and 37% without history of
psychosis) was found. The GRM3 rs6465084 G-allele was
found to increase the odds of having had a psychotic episode
(OR=3.9; p=0.004) considerably. Even after adjusting for
family-relatedness only, a significant association (OR=2.2;
p=0.0137) was observed. 
Reported number of hospitalisations for mania (n=167)
varied between 0 and 11. The interaction between DAOA
rs701567and GRIN2B rs1019385 on number of hospitalisations
for mania was significant (p=0.0108), and this interaction was
independently significant after including other interactions in
the model. The nature of the modelled interaction is illustrated
in Figure 1 and can be described as follows: For individuals
with the GRIN2B rs1019385 genotype G/G, their expected
number of hospitalisations for mania increased with their
number of DAOA rs701567 G alleles. For individuals with the
GRIN2B rs1019385 genotype G/T, there were smaller
decreases in number of hospitalizations and for those
individuals with the T/T genotype, each DAOA rs701567 G
allele resulted in larger decreases. Individuals who are
homozygous A for DAOA rs701567 and homozygous T for
GRIN2B rs1019385 had the largest number of hospitalisations,
and those who are homozygous G for DAOA rs701567 in
combination with being homozygous G for GRIN2B rs1019385,
had the second largest. Those with DAOA rs701567 G/G and
GRIN2B rs1019385 T/T had the least number of hospitalisations. 
Discussion
The first set of findings related to SNP frequency showed that
all 3 SNPs examined had a similar distribution between
Caucasian and mixed ancestry groups, and that BD diagnosis
was not associated with any of the SNPs examined. The
second set of findings, related to BD severity, was that the non-
ancestral GRM3 G allele at rs6465084 carries a 4 times
greater risk of developing psychosis in BD subjects, and that
alleles at DAOA rs701567 and GRIN2B rs1019385 interact such
that the risk of hospital admission is higher with a greater
number of non-ancestral alleles. 
This is the first time that allele frequencies in the candidate
genes studies here have been described for the mixed
ancestry population of South Africa. SNP frequencies were
broadly similar to reported frequencies for Caucasian groups
described elsewhere (NCBI http://www.ncbi.nlm.nih.gov).22 No
difference in frequency was detected for the ancestral allele
for GRM3 rs6465084 and of GRIN2B rs1019385 in individuals
of both Caucasian and mixed ancestry. The A/G alleles of
DAOA rs701567 were found to occur at almost equal
Figure 1: A three dimensional bar chart illustrating the
modelled interaction of DAOA rs701567 and GRIN2B
rs1019385 on the logarithm of the number of
hospitalisations for mania.
Table I: SNP Allele Frequencies For Each of the Candidate Genes
Gene SNP Ethnic Group No. of Cases No. of Controls Ancestral Allele Ancestral Allele p-value
Frequency Cases Frequency Controls
GRM3 rs6465084 Caucasian, Mixed Ancestry 132 188 0.75 0.77 0.5953
Caucasian only 69 89 0.73 0.78 0.3054
Mixed Ancestry only 63 99 0.77 0.76 0.7887
GRIN2B rs1019385 Caucasian, Mixed Ancestry 132 188 0.35 0.34 0.8268
Caucasian only 69 89 0.41 0.40 0.9181
Mixed Ancestry only 63 99 0.29 0.28 0.8304
DAOA rs701567 Caucasian, Mixed Ancestry 132 188 0.43 0.48 0.2000
Caucasian only 69 89 0.41 0.41 0.8961
Mixed Ancestry only 63 99 0.45 0.56 0.0725
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frequencies in both population groups. 
We did not demonstrate that any of the putative risk alleles
were associated with BD diagnosis. This is consistent with the
lack of consistently reproducible associations between individual
genes and BD diagnosis even in large data sets.33 There is
increasing evidence that BD is a disorder where many genes of
small effect contribute to risk of developing the disorder.20
In this study, we observed that the G allele at SNP
rs6465084 GRM3 carries a 4 times greater risk of developing
psychosis in subjects with BD. This is unexpected as the A
allele in this SNP has been weakly associated with SZ
diagnosis– and might be expected to be a risk factor for
psychosis in BD.20 This finding by Egan et al., however, was not
replicated by others.34,35 Egan et al. also reported an
association between the A allele, impaired list learning and
verbal fluency, and low prefrontal levels of glutamate
transporter EEAT2 in normal subjects and people with SZ.20 It
is possible to speculate that the A allele confers a risk of a
dysexecutive syndrome typical of certain types of SZ, while the
G allele is associated with normal or enhanced executive
function, consistent with the finding by Diller et al. that GRM3 is
a gene which has evolved favourable new (derived) alleles.36
The G allele may, however, together with other risk factors, be
associated with more severe mania. Crespi et al. identified
GRM3 as a gene with significant evidence of selection in
human populations, and although not enough is known about
this SNP in global populations or its function in normal or
disease states, it may be one which differentiates Kraepelinean
“dementia praecox” from “manic depression”.19,37
The rs701567 SNP in DAOA was not associated with BD
diagnosis in this study, contrary to the finding of Fallin et al.16
The G allele was not associated with any phenotype or severity
measures; however there was a significant gene-gene
interaction with GRIN2B rs1019385 SNP on the number of
hospitalisations for mania. In the South African context,
hospitalisation is most often required for emergency treatment
of severe episodes. The combination of both ancestral alleles
(G for DAOA and T for GRIN2B) conferred the lowest risk of
admission while homozygotes with a derived allele/ancestral
allele combination had the highest risk for hospitalisation.
Homozygotes for both derived alleles had a relatively low risk
of hospitalisation. DAOA activates DAO which determines
synaptic glutamate and serine levels, while NMDA receptor
function varies according to glutamate levels and GRIN2B
genotype. Both DAOA and GRIN2B form part of the
phosphoinositide-3 kinase/ AKT-signalling network (PI3K/AKT),
involved in the regulation of cell proliferation, growth,
development and apoptosis.38,39 We may speculate that
heterozygotes have intermediate glutamate function and
homozygotes an inflexible regulatory capacity for glutamate
load or deficiency states, compromising normal neural
development and plasticity.
A major limitation of this study was the relatively small
sample size. To avoid this, recent studies have focussed on
obtaining large consortia for genetic association tests. An
example of this would be the Wellcome Trust Case Control
Consortium which investigated the genetic basis of seven
common diseases, including BD, using 2000 affected
individuals for each disorder and 3000 shared controls. The
outcome of this study was that modest genetic effects were
able to be detected using larger sample sizes.40
The most constraining limitation of the current study is the
lack of information about the in vivo and in vitro function of the
specific SNPs examined. Future work is needed to determine the
functionality of glutamate SNPs in terms of gene expression and
physiological correlates, and whether these link to phenotypes
for BD. The interaction between DAOA rs701567 and GRIN2B
rs1019385 may be indirect or direct and if direct could be
examined with a protein interaction assay such as yeast-2-hybrid
screen. Other SNPs in the genes we examined and other genes
involved in glutamate metabolism including glutamate receptor,
ionotropic, N-methyl D-aspartate 1 (GRIN1), glutamate receptor,
metabotropic 1 (GRM1) and glutamate receptor, ionotropic,
kainate 1 (GRIK1) and their interactions with BD phenotypes
should also be explored. Another consideration for future work
would be to have greater detail regarding cognitive phenotype.
This could be helpful to test (post-hoc) hypotheses related to
cognitive function in, for example, controls with GRM3 rs6465084
derived allele homozygotes.
Conclusion
To our knowledge this is the first study investigating these 3
glutamatergic SNPs and their interactions with BD diagnosis
and phenotype. The study provided preliminary evidence that
ancestral alleles in the 3 SNPs examined have a protective
effect by decreasing the chances of having more severe
phenotypes of BD, specifically psychosis and repeat hospital
admission. It is possible to speculate that newly derived genes
associated with various evolutionary advantages (including
perhaps cognitive advantages), may also increase the risk for
more severe bipolar disorder. However, findings from this pilot
study warrant further research and validation. 
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